Neurocrine Biosciences, Inc. (NBIX)
132.56
+0.82
(+0.62%)
USD |
NASDAQ |
Apr 01, 16:00
132.63
+0.07
(+0.05%)
After-Hours: 20:00
Neurocrine Biosciences Research and Development Expense (TTM) : 1.016B for Dec. 31, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Glaukos Corp. | 150.61M |
| Edgewise Therapeutics, Inc. | 149.30M |
| Nuvalent, Inc. | 306.97M |
| Agenus, Inc. | 79.34M |
| Curis, Inc. | 28.25M |